IRESSA (Gefitinib)-20mg

IRESSA (Gefitinib) is a targeted therapy called a tyrosine kinase inhibitor (TKI), blocks a certain protein (an enzyme called tyrosine kinase), signals transduction inhibitor-epidermal growth factor receptor (EGFR) inhibits the activity that contributes to intracellular signaling pathways implicated in the growth and survival of cancer cells.

IRESSA is indicated for the first-line treatments of metastatic non- small cell lung cancer (NSCLC). It is used in patients in which it has spread to other parts of the body, who have abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer.